Back to Search Start Over

[Safety and efficacy of the Relatox in the treatment of patients with cervical dystonia (results of a multicenter simple blind comparative randomized study)].

Authors :
Khatkova SE
Orlova OR
Pokhabov DV
Diagileva VP
Novikov SA
Pogoreltseva OA
Shevchenko VS
Nikolaev EA
Source :
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2022; Vol. 122 (11), pp. 80-85.
Publication Year :
2022

Abstract

Objective: The analysis of evaluation of the efficacy and safety of Relatox in patients with cervical dystonia (CD).<br />Material and Methods: Russian multicenter simple comparative randomized clinical trial. The study involved 180 patients of both sexes aged 18-65 years from 3 research centers of the Russian Federation. All patients had previously established diagnosis of CD and were randomized to one of two groups at 1 visit after the inclusion procedure and signing of informed consent. Patients in group 1 ( n =90) got injections of Relatox, in group 2 ( n =90) - injections of Botox for the first time or no earlier than 4 months after the previous injection of Dysport 500 units, Botox 200 units or Xeomin 200 units. The assessment of changes in cervical dystonia followed, including of determination of changes in the severity of CD, assessed on the TWSTRS scale by the total score and by the defining values of the blocks, as well as on the scales: the Patient Global Impression of Improvement (PGI-I) and of adverse events (local and systemic reactions). Based on the form of cervical dystonia (torticollis, laterocollis, etc.), the drug was injected under electromyographic control into the target muscles: sternocleidomastoid, belt, trapezoidal, shoulder-lifting muscle.<br />Results: Equal efficacy, good tolerability and safety comparable to the comparison drug Botox was demonstrated in 12 weeks after injection of Relatox. The number of registered local and systemic reactions in both groups was insignificant and did not differ significantly ( p >0.05). There were no significant differences in the results of laboratory parameters in patients of both groups ( p >0.05). Serious adverse events were also not detected during the study.<br />Conclusion: Obtained results indicate the safety, good tolerability and efficacy of Relatox in patients with CD comparable to Botox and can be recomemded for using by practitioners.

Details

Language :
Russian
ISSN :
1997-7298
Volume :
122
Issue :
11
Database :
MEDLINE
Journal :
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Publication Type :
Academic Journal
Accession number :
36440782
Full Text :
https://doi.org/10.17116/jnevro202212211180